Key result
Pimobendan added to standard therapy significantly improved heart failure class in dogs with dilated cardiomyopathy (80% vs 10%; P=0.005) and prolonged survival in Doberman Pinschers.
Why the study?
Does pimobendan improve heart failure class and survival in dogs with dilated cardiomyopathy?
RCT (n=20)
Double-blind
Randomized
Does pimobendan improve heart failure class and survival in dogs with dilated cardiomyopathy?
Absolute Event Rate: 80% vs 10%
p-value: p=0.005
Pimobendan improves heart failure functional class in dogs with dilated cardiomyopathy and significantly prolongs survival in Doberman Pinschers.
No takes yet. Share an insight, caveat, or question.
Supports adding pimobendan to standard therapy for canine DCM; confirms RCT benefit and extends survival data to Dobermans.
Fuentes et al. (2002) conducted an RCT in Dilated cardiomyopathy (n=20). Pimobendan vs. Placebo was evaluated on Improvement in heart failure status by at least 1 modified NYHA functional class (p=0.005). Pimobendan added to standard therapy significantly improved heart failure class in dogs with dilated cardiomyopathy (80% vs 10%; P=0.005) and prolonged survival in Doberman Pinschers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: